Antibody-Associated Polyneuropathy Syndromes: Principles and Treatment

Andrew J. Kornberg; Alan Pestronk

doi:10.1055/s-2003-41131

Seminars in Neurology, Inhaltsverzeichnis

Semin Neurol 2003; 23(2): 181-190
DOI: 10.1055/s-2003-41131

Antibody-Associated Polyneuropathy Syndromes: Principles and Treatment

Andrew J. Kornberg^1,2 , Alan Pestronk³

¹Department of Neurology, Royal Children's Hospital, Parkville, Victoria, Australia
²Melbourne Neuromuscular Research Institute, St. Vincent's Hospital, Fitzroy, Victoria, Australia
³Department of Neurology, Washington University School of Medicine, St. Louis, Missouri

Abstract

ABSTRACT

Treatment of immune-mediated neuropathies first requires an accurate diagnosis. The diagnosis is often based on clinical, electrophysiological, and immunological features of the syndrome. The selection of appropriate therapies is then based on the spectrum of response of a syndrome to medications and an assessment of possible side effects. In neuropathies with associated serum immunoglobulin M autoantibodies, such as anti-myelin-associated glycoprotein and motor syndromes, the choices of therapy are often limited to cytotoxic agents and, in some cases, intravenous immunoglobulin. In neuropathies with immunoglobulin G antibodies in both serum and cerebrospinal fluid, such as sensory neuronopathies associated with anti-Hu antibodies, there is no well-documented response to any immunotherapy. The general principles regarding therapy of immune neuropathies will be discussed with a focus on diagnosis and treatment options of the demyelinating and immunoglobulin M antibody-associated neuropathies.

KEYWORDS

IgM - antibody - neuropathy - intravenous immunoglobulin - cyclophosphamide - rituximab

Volltext

Referenzen

REFERENCES

1 Van den Berg-Vos M R, Franssen H, Wokke J H, van den Berg H L. Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment. Brain . 2002; 125 1875-1886
2 Mendell J R, Barohn R J, Freimer M L. et al . Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology . 2001; 56 445-449
3 Federico P, Zochodne D W, Hahn A F, Brown W F, Feasby T E. Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology . 2000; 55 1256-1262
4 Van Doorn A P, van der Meché G A F. IVIg treatment improves multifocal motor neuropathy: easy to start but difficult to stop. Neurology . 2000; 55 1246-1247
5 Pestronk A. Multifocal motor neuropathy: diagnosis and treatment. Neurology . 1998; 51 (suppl 5) S22-S24
6 Hahn A F, Bolton C F, Pillay N. et al . Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy: a double-blind, sham-controlled, cross-over study. Brain . 1996; 119 1055-1066
7 Hahn A F, Bolton C F, Zochodne D, Feasby T E. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, cross-over study. Brain . 1996; 119 1067-1077
8 Gorson K C, Allam G, Ropper A H. Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology . 1997; 48 321-328
9 van den Berg H L, Lokhorst H, Wokke J HJ. Pulsed high-dose dexamethasone is not effective in patients with multifocal motor neuropathy. Neurology . 1997; 48 1135
10 van den Berg H L, Kerkhoff H, Oey P L. et al . Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry . 1995; 59 248-252
11 Pestronk A, Lopate G, Kornberg A J. et al . Distal lower motor neuron syndrome with high titer serum IgM anti-GM1 antibodies: improvement following immunotherapy with monthly plasma exchange and intravenous cyclophosphamide. Neurology . 1994; 44 2027-2031
12 Elliott J L, Pestronk A. Deterioration of multifocal motor neuropathy during apparently successful treatment with human immune globulin. Neurology . 1994; 44 967-968
13 Vincent A. Antibodies to ion channels in paraneoplastic disorders. Brain Pathol . 1999; 9 285-291
14 Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med . 2001; 7 365-368
15 Lindstrom J M. Acetylcholine receptors and myasthenia. Muscle Nerve . 2000; 23 453-477
16 Greenberg D A. Neuromuscular disease and calcium channels. Muscle Nerve . 1999; 22 1341-1349
17 Meriney S D, Hulsizer S C, Lennon V A, Grinnell A D. Lambert-Eaton myasthenic syndrome immunoglobulins react with multiple types of calcium channels in small-cell lung carcinoma. Ann Neurol . 1996; 40 739-749
18 Kullmann D M. The neuronal channelopathies. Brain . 2002; 125 1177-1195
19 Dalmau J, Gultekin H S, Posner J B. Paraneoplastic neurologic syndromes: pathogenesis and physiopathology. Brain Pathol . 1999; 9 275-284
20 Graus F, Keime-Guibert F, Rene R. et al . Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain . 2001; 124 1138-1148
21 Rudnicki S A, Dalmau J. Paraneoplastic syndromes of the spinal cord, nerve, and muscle. Muscle Nerve . 2000; 23 1800-1818
22 Manley G T, Smitt P S, Dalmau J, Posner J B. Hu antigens: reactivity with Hu antibodies, tumor expression, and major immunogenic sites. Ann Neurol . 1995; 38 102-110
23 Jaeckle K A. Autoimmunity in paraneoplastic neurological syndromes: closer to the truth?. Ann Neurol . 1999; 45 143-145
24 Steck A J, Erne B, Gabriel J M, Schaeren-Wiemers N. Paraproteinaemic neuropathies. Brain Pathol . 1999; 9 361-368
25 Levine T D, Pestronk A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab. Neurology . 1999; 52 1701-1704
26 Pestronk A, Cornblath D R, Ilyas A. et al . A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol . 1988; 24 73-78
27 Feldman E L, Bromberg M B, Albers J W, Pestronk A. Immunosuppressive treatment in multifocal motor neuropathy. Ann Neurol . 1991; 30 397-401
28 Blume G, Pestronk A, Goodnough L T. Anti-MAG antibody-associated polyneuropathies: improvement following immunotherapy with monthly plasma exchange and IV cyclophosphamide. Neurology . 1995; 45 1577-1580
29 Nobile-Orazio E, Meucci N, Baldini L, Di Troia A, Scarlato G. Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain . 2000; 123 710-717
30 Kornberg A J, Pestronk A. The clinical and diagnostic role of anti-GM1 antibody testing. Muscle Nerve . 1994; 17 100-104
31 Lopate G, Choksi R, Pestronk A. Severe sensory ataxia and demyelinating polyneuropathy with IgM anti-GM2 and GalNAc-GD1A antibodies. Muscle Nerve . 2002; 25 828-836
32 Ho T W, Willison H J, Nachamkin I. et al . Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barré syndrome. Ann Neurol . 1999; 45 168-173
33 Lopate G, Kornberg A J, Yue J, Choksi R, Pestronk A. Anti-myelin associated glycoprotein antibodies: variability in patterns of IgM binding to peripheral nerve. J Neurol Sci . 2001; 188 67-72
34 Pestronk A, Li F, Bieser K. et al . Anti-MAG antibodies: major effects of antigen purity and antibody cross-reactivity on ELISA results and clinical correlation. Neurology . 1994; 44 1131-1137
35 Pestronk A, Li F, Griffin J. et al . Polyneuropathy syndromes associated with serum antibodies to sulfatide and myelin-associated glycoprotein. Neurology . 1991; 41 357-362
36 Kyle R A, Dyck P J. Osteosclerotic myeloma (POEMS syndrome). In: Dyck PJ, Thomas PK, Griffin JW, Low PA, Poduslo JF, eds. Peripheral Neuropathy Philadelphia: WB Saunders 1993: 1288-1293
37 Latov N. Pathogenesis and therapy of neuropathies associated with monoclonal gammopathies. Ann Neurol . 1995; 37 (suppl 1) S32-S42
38 Ropper A H, Gorson K C. Neuropathies associated with paraproteinemia. N Engl J Med . 1998; 338 1601-1607
39 Pestronk A. Paraneoplastic syndromes. Available at: http:// www.neuro.wustl.edu/neuromuscular. Accessed July 2002
40 Dropcho E J. Neurologic paraneoplastic syndromes. J Neurol Sci . 1998; 153 264-278
41 Scaravilli F, An S F, Groves M, Thom M. The neuropathology of paraneoplastic syndromes. Brain Pathol . 1999; 9 251-260
42 Giometto B, Scaravilli F. Paraneoplastic syndromes. Brain Pathol . 1999; 9 247-250
43 Giometto B, Taraloto B, Graus F. Autoimmunity in paraneoplastic neurological syndromes. Brain Pathol . 1999; 9 261-273
44 Grisold W, Drlicek M. Paraneoplastic neuropathy. Curr Opin Neurol . 1999; 12 617-625
45 Gultekin S H, Rosenfeld M R, Voltz R, Eichen J, Posner J B, Dalmau J. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain . 2000; 123 1481-1494
46 Dalmau J O, Posner J B. Neurological paraneoplastic syndromes. Neuroscientist . 1998; 4 443-453
47 Erb S, Ferracin F, Fuhr P. et al . Polyneuropathy attributes: a comparison between patients with anti-MAG and anti-sulfatide antibodies. J Neurol . 2000; 247 767-772
48 Nobile-Orazio E. Neuropathies associated with anti-MAG antibodies and IgM monoclonal gammopathies. In: Latov N, Wokke JHJ, Kelly JJ Jr, eds. Immunology and Infectious Diseases of the Peripheral Nerves Cambridge, UK: Cambridge University Press 1998: 168-189
49 Kaku D A, England J D, Sumner A J. Distal accentuation of conduction slowing in polyneuropathy associated with antibodies to myelin-associated glycoprotein and sulphated glucuronyl paragloboside. Brain . 1994; 117 941-947
50 Van den Berg L, Hays A P, Nobile Orazio E. et al . Anti-MAG and anti-SGPG antibodies in neuropathy. Muscle Nerve . 1996; 19 637-643
51 Weiss M D, Dalakas M C, Lauter C J, Willison H J, Quarles R H. Variability in the binding of anti-MAG and anti-SGPG antibodies to target antigens in demyelinating neuropathy and IgM paraproteinemia. J Neuroimmunol . 1999; 95 174-184
52 Lopate G, Parks B J, Goldstein J M, Yee W C, Friesenhahn G M, Pestronk A. Polyneuropathies associated with high titre antisulphatide antibodies: characteristics of patients with and without serum monoclonal proteins. J Neurol Neurosurg Psychiatry . 1997; 62 581-585
53 Petratos S, Turnbull V J, Papadopoulos R, Ayers M, Gonzales M F. High-titre IgM anti-sulfatide antibodies in individuals with IgM paraproteinaemia and associated peripheral neuropathy. Immunol Cell Biol . 2000; 78 124-132
54 Carpo M, Meucci N, Allaria S. et al . Anti-sulfatide IgM antibodies in peripheral neuropathy. J Neurol Sci . 2000; 176 144-150
55 Petratos S, Turnbull V J, Papadopoulos R, Ayers M, Gonzales M F. High titre anti-sulphatide antibodies in HIV-infected individuals. Neuroreport . 1999; 10 2557-2562
56 Avila J L, Rojas M, Carrasco H. Elevated levels of antibodies against sulphatide are present in all chronic chagasic and non-chagasic dilatatory cardiomyopathy sera. Clin Exp Immunol . 1993; 92 460-465
57 Pestronk A, Choksi R, Bieser K. et al . Treatable gait disorder and polyneuropathy associated with high titer serum IgM binding to antigens that copurify with myelin-associated glycoprotein. Muscle Nerve . 1994; 17 1293-1300
58 Pestronk A. Autoantibodies and Immune polyneuropathies. In: Katirji B, Kaminski HJ, Preston DC, Ruff RL, Shapiro BE, eds. Neuromuscular Disorders in Clinical Practice Boston: Butterworth-Heinemann 2002: 64-73
59 Susuki K, Yuki N, Hirata K. Features of sensory ataxic neuropathy associated with anti-GD1b IgM antibody. J Neuroimmunol . 2001; 112 181-187
60 Ponsford S, Willison H, Veitch J, Morris R, Thomas P K. Long-term clinical and neurophysiological follow-up of patients with peripheral neuropathy associated with benign monoclonal gammopathy. Muscle Nerve . 2000; 23 164-174
61 Nobile-Orazio E. Multifocal motor neuropathy. J Neuroimmunol . 2001; 115 4-18
62 Nobile-Orazio E, Cappellari A, Meucci N. et al . Multifocal motor neuropathy: clinical and immunological features and response to IVIg in relation to the presence and degree of motor conduction block. J Neurol Neurosurg Psychiatry . 2002; 72 761-766
63 Parry G J. AAEM case report #30: multifocal motor neuropathy. Muscle Nerve . 1996; 19 269-276
64 Saperstein D S, Katz J S, Amato A A, Barohn R J. Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve . 2001; 24 311-324
65 Pestronk A, Choksi R. Multifocal motor neuropathy: serum IgM anti-GM1 ganglioside antibodies in most patients detected using covalent linkage of GM1 to ELISA plates. Neurology . 1997; 49 1289-1292
66 Taylor B V, Wright R A, Harper C M, Dyck P J. Natural history of 46 patients with multifocal motor neuropathy with conduction block. Muscle Nerve . 2000; 23 900-908
67 Van den Berg H L, Franssen H, Wokke J HJ. The long-term effect of intravenous immunoglobulin treatment in multifocal motor neuropathy. Brain . 1998; 121 421-428
68 Leger J M, Chassande B, Musset L, Meininger V, Bouche P, Baumann N. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain . 2001; 124 145-153
69 Van den Berg-Vos M R, Franssen H, Wokke J H, Van den Berg H L. Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment. Brain . 2002; 125 1875-1886
70 Kaji R, Kusunoki S, Mizutani K. et al . Chronic motor axonal neuropathy associated with antibodies monospecific for N-acetylgalactosaminyl GD1a. Muscle Nerve . 2000; 23 702-706
71 Ortiz N, Rosa R, Gallardo E. et al . IgM monoclonal antibody against terminal moiety of GM2, GalNAc-GD1a and GalNAc-GM1b from a pure motor chronic demyelinating polyneuropathy patient: effects on neurotransmitter release. J Neuroimmunol . 2001; 119 114-123
72 Connolly A M, Pestronk A, Mehta S. et al . Serum IgM monoclonal autoantibody binding to the 301 to 314 amino acid epitope of b-tubulin: clinical association with slowly progressive demyelinating polyneuropathy. Neurology . 1997; 48 243-248
73 Miralles G D, O'Fallon J R, Talley N J. Plasma-cell dyscrasia with polyneuropathy: the spectrum of POEMS syndrome. N Engl J Med . 1992; 327 1919-1923